| Literature DB >> 24904027 |
Stefan D Anker1, Stefan Agewall2, Martin Borggrefe3, Melanie Calvert4, J Jaime Caro5, Martin R Cowie6, Ian Ford7, Jean A Paty8, Jillian P Riley9, Karl Swedberg10, Luigi Tavazzi11, Ingela Wiklund12, Paulus Kirchhof13.
Abstract
Patient-reported outcomes (PROs), such as symptoms, health-related quality of life (HRQOL), or patient perceived health status, are reported directly by the patient and are powerful tools to inform patients, clinicians, and policy-makers about morbidity and 'patient suffering', especially in chronic diseases. Patient-reported outcomes provide information on the patient experience and can be the target of therapeutic intervention. Patient-reported outcomes can improve the quality of patient care by creating a holistic approach to clinical decision-making; however, PROs are not routinely used as key outcome measures in major cardiovascular clinical trials. Thus, limited information is available on the impact of cardiovascular therapeutics on PROs to guide patient-level clinical decision-making or policy-level decision-making. Cardiovascular clinical research should shift its focus to include PROs when evaluating the efficacy of therapeutic interventions, and PRO assessments should be scientifically rigorous. The European Society of Cardiology and other professional societies can take action to influence the uptake of PRO data in the research and clinical communities. This process of integrating PRO data into comprehensive efficacy evaluations will ultimately improve the quality of care for patients across the spectrum of cardiovascular disease. Published on behalf of the European Society of Cardiology. All rights reserved.Entities:
Keywords: Cardiovascular clinical trials; Health-related quality of life; Patient-reported outcomes
Mesh:
Year: 2014 PMID: 24904027 DOI: 10.1093/eurheartj/ehu205
Source DB: PubMed Journal: Eur Heart J ISSN: 0195-668X Impact factor: 29.983